A Randomized Phase 2 Clinical Trial of IMC-A12, as a Single Agent or in Combination With Cetuximab, in Patients With Metastatic Colorectal Cancer With Disease Progression on Prior Anti-EGFR Therapy.

Trial Profile

A Randomized Phase 2 Clinical Trial of IMC-A12, as a Single Agent or in Combination With Cetuximab, in Patients With Metastatic Colorectal Cancer With Disease Progression on Prior Anti-EGFR Therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2010

At a glance

  • Drugs Cetuximab; Cixutumumab
  • Indications Colorectal cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors ImClone Systems
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Aug 2010 Results published in the Journal of Clincal Oncology.
    • 16 Aug 2010 Status changed from active, no longer recruiting to completed, based on an article published in the Journal of Clincal Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top